AlginoMAX chewable tablets №14х2

Name:
Alginomax. Release form Chewable tablets.
Description:
Tablets are oval biconvex from white to white with a yellowish or brownish tinge of color with patches of a darker color. Excipients; hydroxyapatite (E341), polyethylene glycol (macrogol) 6000, copovidone, sodium saccharin (E954), sorbitol (E420), magnesium stearate (E572), levomenthol. Pharmacotherapeutic group Other anti-ulcer diseases and agents for the treatment of gastroesophageal reflux disease (GERD). ATC/ATS code: A02BX gel about 7). Alginate gel prevents the reflux of stomach contents into the esophagus, and in case of regurgitation or reflux, the gel enters the esophagus, where it has a neutralizing effect on hydrochloric acid and pepsin that enter during reflux and additionally protects the esophageal mucosa. In severe cases of reflux, the gel is thrown into the esophagus, ahead of the rest of the gastric contents, and reduces irritation of the gastric mucosa. Pharmacodynamics The mechanism of antireflux action of the drug AlginoMAX is associated with the formation of a physical barrier that prevents reflux, and has no systemic effect. patients with symptoms caused by reflux esophagitis. Method of application and dosing regimen Tablets are taken orally after thorough chewing with a glass of drinking water. Adults and children over 12 years old – 2-4 tablets four times a day 30-40 minutes after breakfast, lunch, dinner and at bedtime. If the prescribed dose is missed, continue taking the drug as usual, according to the recommended regimen. Do not take a double dose to make up for the missed one. Duration of treatment If after 7 days of taking the drug the symptoms persist, it is necessary to consult a doctor to review the treatment. Use in children AlginoMAX is not intended for use in children under 12 years of age due to limited data on safety and efficacy Use in elderly patients Usually no dose adjustment is required. Caution should be exercised due to the higher incidence of kidney and cardiovascular diseases in this age group of patients (see section “Precautions”). Use in patients with impaired liver function Dose changes are not required. Use in patients with impaired renal function, chronic heart failure Use with caution if a diet with a very limited salt intake is required. Do not exceed recommended doses! In patients with impaired renal function and / or who are on chronic dialysis, long-term use of high doses of magnesium may cause hypermagnesemia (see section “Precautions”). Contraindications Increased individual sensitivity to any of the ingredients of the drug. Severe renal failure (due to the presence of magnesium), rare congenital fructose intolerance, children under 12 years of age (insufficient data on safety and efficacy of use). OverdoseSymptoms: Abdominal bloating is possible. An overdose of magnesium and calcium usually does not cause symptoms in patients with normal kidney function. Patients with impaired renal function may experience symptoms due to the occurrence of hypermagnesemia, hypercalcemia and hyperkalemia. Treatment: symptomatic. In case of renal insufficiency, hemodialysis or peritoneal dialysis may be necessary. Interaction with other drugs is not known. It is recommended to observe a time interval of 2 hours between taking the drug AlginoMAX and other drugs, especially when taken simultaneously with antimicrobial agents from the group of tetracyclines and fluoroquinolones, ketoconazole, digoxin, iron salts, neuroleptics, thyroid hormones, beta-blockers (atenolol, metoprolol, propranolol), glucocorticoids, penicillamine, chloroquine, estramustine and bisphosphonates. Use during pregnancy and lactation The safety of AlginoMAX during pregnancy has not been established. Due to the limited data on the efficacy and safety of the drug, use during pregnancy is possible only after consulting a doctor and assessing the ratio of benefit to the mother and risk to the fetus. Use during breastfeeding is possible, with appropriate monitoring of the condition, not exceeding the recommended duration (see section “Method of application and dosage regimen”). The effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms and work with machinery. Side effects The frequency of occurrence of adverse reactions was assessed based on the following criteria: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥ 1/10000, <1/1000), very rarely (<1/10000) and unspecified frequency (the frequency cannot be calculated from the available data). Immune system disorders: very rarely - anaphylactic and anaphylactoid reactions, hypersensitivity reactions (such like hives). Respiratory, thoracic and mediastinal disorders: very rare - respiratory effects (such as bronchospasm). Gastrointestinal disorders: frequency unknown - diarrhea, flatulence. Others: with prolonged use of high doses, the formation of kidney stones, the occurrence of alkalosis, hypermagnesemia, hypercalcemia are possible, therefore, the recommended doses and duration of administration should not be exceeded. If you experience any of these or any other adverse reactions not listed in this leaflet, you should consult a doctor. Precautions If after 7 days of taking the drug the symptoms persist, you should consult a doctor to review the treatment. Patients are also advised to consult a doctor if they have symptoms such as: weight loss; difficulty swallowing or a feeling of constant discomfort in the abdomen; indigestion that appeared for the first time or in case of changes in existing digestive disorders; kidney failure. The content of sorbitol in one tablet is 284 mg, in a dose of two tablets - 568 mg, in a dose of 8 tablets - 2272 mg, in a dose of 16 tablets - 4544 mg. If you have intolerance to some sugars, you should consult your doctor before use. The sodium content in one tablet is 29 mg (1.26 mmol), in a dose of two tablets - 58 mg (2.52 mmol), in a dose of 8 tablets - 232 mg (10.08 mmol), in a dose of 16 tablets - 464 mg (20.16 mmol). Should be taken into account when treating patients on a low sodium diet. The potassium content in one tablet is 29.25 mg (0.75 mmol), at a dose of two tablets - 58.5 mg (1.5 mmol), at a dose of 8 tablets - 234 mg (6 mmol) at a dose of 16 tablets - 468 mg (12 mmol). Should be taken into account when treating patients on a low potassium diet. The content of calcium in the form of calcium carbonate and hydroxyapatite in one tablet is 60 mg (1.5 mmol), at a dose of two tablets - 120 mg (3 mmol), at a dose of 8 tablets - 480 mg (12 mmol), at a dose of 16 tablets - 960 mg (24 mmol). It should be taken into account when treating patients with hypercalcemia, nephrocalcinosis and the presence of recurrent calcium-containing kidney stones. The content of magnesium in the form of magnesium hydroxide and magnesium stearate in one tablet is 19.1 mg (0.8 mmol), in a dose of two tablets - 38.2 mg (1.6 mmol), in a dose of 8 tablets - 152.8 mg ( 6.4 mmol), at a dose of 16 tablets - 305.6 mg (12.8 mmol). In patients with renal insufficiency and those on chronic dialysis, an increase in the content of magnesium in the blood plasma and the appearance of associated symptoms may occur. With a decrease in kidney function, long-term use of the drug AlginoMAX should be avoided, the use is contraindicated in patients with severe renal insufficiency. Storage conditions Store in a place protected from moisture and light at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 3 years. Do not use after the expiry date stated on the package. Packing: 14 tablets in a blister pack; two blister packs in a carton box along with instructions for use Conditions for dispensing from pharmacies Without a prescription. Buy AlginoMAX chewable tablets No. 14x2 Price for AlginoMAX chewable tablets No. 14x2